Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: Is there a role for tamoxifen?

Future Oncology

Volumn 10, Issue 4, 2014, Pages 499-502

  Phillips, Kelly Anne ^a,b   Lindeman, Geoffrey J ^b,c,d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

BRCA1; BRCA2; breast cancer; chemoprevention; denosumab; prevention; progesterone; RANKL; tamoxifen

Indexed keywords

TAMOXIFEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BRCA2 GENE; BREAST CANCER; DRUG EFFICACY; FEMALE; GENE MUTATION; HUMAN; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT; BREAST NEOPLASMS; CHEMOPROPHYLAXIS; GENETICS; HETEROZYGOTE; MUTATION;

BREAST NEOPLASMS; CHEMOPREVENTION; FEMALE; GENES, BRCA1; GENES, BRCA2; HETEROZYGOTE; HUMANS; MUTATION; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 84899479365     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.278     Document Type: Review

References (27)

1. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am. J. Hum. Genet. 72(5), 1117-1130 (2003
2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Breast cancer risk reduction version 1 (2013). www.nccn.org/ professionals/physician-gls/f- guidelines.asp#breast-risk
3. Collins IM, Milne RL, Weideman PC et al. Preventing breast and ovarian cancers in highrisk BRCA1 and BRCA2 mutation carriers. Med. J. Aust. 199(10), 680-683 (2013
4. Cuzick J, Sestak I, Bonanni B et al. Selective oestrogen receptor modulators in prevention of breast cancer: An updated meta-Analysis of individual participant data. Lancet 381(9880), 1827-1834 (2013
5. King MC, Wieand S, Hale K et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286(18), 2251-2256 (2001
6. Phillips KA, Milne RL, Rookus MA et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 31(25), 3091-3099 (2013
7. Gronwald J, Tung N, Foulkes WD et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. Int. J. Cancer 118(9), 2281-2284 (2006
8. Reding KW, Bernstein JL, Langholz BM et al. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Res. Treat. 123(2), 491-498 (2010
9. Pierce LJ, Levin AM, Rebbeck TR et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-Associated stage I/II breast cancer. J. Clin. Oncol. 24(16), 2437-2443 (2006
10. Metcalfe K, Lynch HT, Ghadirian P et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 22(12), 2328-2335 (2004
11. Phillips KA. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J. Clin. Oncol. 18(21 Suppl.), 107S-112S (2000
12. Fan S, Wang J, Yuan R et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284(5418), 1354-1356 (1999
13. Jones LP, Tilli MT, Assefnia S et al. Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer. Oncogene 27(6), 794-802 (2008
14. Antoniou AC, Kartsonaki C, Sinilnikova OM et al. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum. Mol. Genet. 20(16), 3304-3321 (2011
15. Mote PA, Leary JA, Avery KA et al. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. Genes Chrom. Cancer 39(3), 236-248 (2004
16. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314(5804), 1467-1470 (2006
17. Anderson E, Clarke RB. Steroid receptors and cell cycle in normal mammary epithelium. J. Mammary Gland Biol. Neoplasia 9(1), 3-13 (2004
18. Beleut M, Rajaram RD, Caikovski M et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc. Natl Acad. Sci. USA 107(7), 2989-2994 (2010
19. Asselin-Labat ML, Vaillant F, Sheridan JM et al. Control of mammary stem cell function by steroid hormone signalling. Nature 465(7299), 798-802 (2010
20. Joshi PA, Jackson HW, Beristain AG et al. Progesterone induces adult mammary stem cell expansion. Nature 465(7299), 803-807 (2010
21. Lim E, Vaillant F, Wu D et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat. Med. 15(8), 907-913 (2009
22. Keogh LA, Hopper JL, Rosenthal D, Phillips KA. Australian clinicians and chemoprevention for women at high familial risk for breast cancer. Hered. Cancer Clin. Pract. 7(1), 9 (2009
23. Nelson HD, Smith ME, Griffin JC, Fu R. Use of medications to reduce risk for primary breast cancer: A systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 158(8), 604-614 (2013
24. Segev Y, Iqbal J, Lubinski J et al. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: An international prospective cohort study. Gynecol. Oncol. 130(1), 127-131 (2013
25. Day R. Quality of life and tamoxifen in a breast cancer prevention trial: A summary of findings from the NSABP P-1 study. National Surgical Adjuvant Breast and Bowel Project. Ann. NY Acad. Sci. 949, 143-150 (2001
26. Pal B, Bouras T, Shi W et al Global changes in the mammary epigenome are induced by hormonal cues and coordinated by Ezh2. Cell Rep. 3(2), 411-426 (2013
27. Lindeman G, Visvader J, Vaillant F et al. Expression of RANK and RANK ligand (RANKL) in breast carcinoma and distinct breast epithelial cells from BRCA1 mutation carriers. Cancer Res. 73(24 Suppl.), P5-03-02 (2013